Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.52 |
| ▸ | GAA | P10253 | 6/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | RECQL | P46063 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28261477 | 0.87 | ALDH1A1 (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1590707 | 0.83 | ALDH1A1 (0.65) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28261471 | 0.78 | ALDH1A1 (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3561171 | 0.78 | KDM4E (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9606773 | 0.78 | ALDH1A1 (0.58) | CA12CA1CA2CA7CA9 | |
| SCHEMBL27948981 | 0.76 | ALDH1A1 (0.57) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6264079 | 0.76 | MEN1 (0.49) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28260153 | 0.76 | ALDH1A1 (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL10305430 | 0.75 | ALDH1A1 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL30881958 | 0.75 | CA12 (0.56) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1278719-B1 | NAPHTHAMIDE NEUROKININ ANTAGONISTS FOR USE AS MEDICAMENTS | ASTRAZENECA AB (SE) | 2005-11-02 | — | — | EP | disclosed |
| US-6903092-B2 | Naphthamide neurokinin antagonists for use as medicaments | ASTRAZENECA AB (SE) | 2005-06-07 | — | — | US | disclosed |
| EP-1119551-B1 | NAPHTHALENECARBOXAMIDES AS TACHYKININ RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2004-12-29 | — | — | EP | disclosed |
| EP-1433783-A2 | Naphthalenecarboxamides as tachykinin receptor antagonists | AstraZeneca AB (SE) | 2004-06-30 | — | — | EP | disclosed |
| US-20030158180-A1 | Naphthamide neurokinin antagonists for use as medicaments | ASTRAZENECA AB (SE) | 2003-08-21 | — | — | US | disclosed |
| EP-1278719-A1 | NAPHTHAMIDE NEUROKININ ANTAGONISTS FOR USE AS MEDICAMENTS | AstraZeneca AB (SE) | 2003-01-29 | — | — | EP | disclosed |
| CN-1322196-A | Naphthalenecarboxamides as tachykinin receptor antagonists | ASTRA ZENECA N N (SE) | 2001-11-14 | — | — | CN | disclosed |
| WO-2001077069-A1 | NAPHTHAMIDE NEUROKININ ANTAGONISTS FOR USE AS MEDICAMENTS | ASTRAZENECA AB (SE) | 2001-10-18 | — | — | WO | disclosed |
| EP-1119551-A1 | NAPHTHALENECARBOXAMIDES AS TACHYKININ RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2001-08-01 | — | — | EP | disclosed |
| WO-2000020389-A1 | NAPHTHALENECARBOXAMIDES AS TACHYKININ RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2000-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158180-A1 | Naphthamide neurokinin antagonists for use as medicaments | NTSR2, NPPA, NPSR1 | CA12 1848/4885CA1 2325/4885CA2 1176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.